Grace Therapeutics, Inc GRCE

Healthcare

Grace Therapeutics, Inc., formerly Acasti Pharma Inc., is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its therapeutic pipeline consists of three clinical-stage drug candidates supported by an intellectual property portfolio of over 40 granted and pending patents in various jurisdictions. Its lead drug candidate, GTX-104, is a clinical-stage, novel, injectable formulation of nimodipine being developed for intravenous (IV) infusion in aneurysmal subarachnoid hemorrhage (aSAH) patients to address significant unmet medical needs. GTX-104 provides a convenient IV delivery of nimodipine in the intensive care unit, eliminating the need for nasogastric tube administration in unconscious or dysphagic patients. Its other pipeline drug candidates include GTX-102, which is an oral-mucosal betamethasone spray for the treatment of Ataxia Telangiectasia and GTX-101, which is a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia.

NDAQ:GRCE - Post by User

Grace Therapeutics, Inc

Bullboard Posts

Comment by andoon May 18, 2018 1:34pm

70 Views

Post# 28053503

RE:RE:RE:news out . Investor relations

From Crescedo "Yes, we will be actively communicating through press releases, and we will be conducting non-deal roadshows across the U.S., as well as conferences and media opportunities." Bottom has definitely been put in. Over the years I've noticed a lot of times stock have a big decline just before powering ahead. This may be one of those times. Insiders loading up.

Bullboard Posts

Cannara reports record growth and profitability in Q4 2023